CD274 and non-small cell lung carcinoma: Furthermore, in a study by Kulasinghe and colleagues [20], 66% of NSCLC patients exhibiting PD-L1+ CTCs (64.7%; n = 11)—enriched through the size-based ClearCell FX—were treated with Nivolumab, but no correlation between PD-L1 expression and clinical outcomes could be observed.